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Abstract: The binding of a popular food supplement and well-known anti-
oxidant, dihydro-alpha-lipoic acid (DHLA) to human serum albumin (HSA) 
was characterised. The binding was monitored by several spectroscopic 
methods together with the molecular docking approach. HSA was able to bind 
DHLA with moderate affinity, 1.00±0.05×104 M-1. Spectroscopic data demon-
strated that the preferential binding site for DHLA on HSA is IIA (Sudlow I). 
Both experimental and molecular docking analysis identified electrostatic (salt 
bridges) and hydrogen bonds as the key interactions involved in DHLA binding 
to HSA. Molecular docking confirmed that the Sudlow I site could accommo-
date DHLA and that the ligand is bound to the protein in a specific conform-
ation. The molecular dynamic simulation showed that the formed complex is 
stable. Binding of DHLA does not affect the structure of the protein, but it 
thermally stabilises HSA. Bound DHLA had no effect on the susceptibility of 
HSA to trypsin digestion. Since DHLA is a commonly used food supplement, 
knowledge of its pharmacokinetics and pharmacodynamic properties in an org-
anism is very important. This study further expands it by providing a detailed 
analysis of its interaction with HSA, the primary drug transporter in the circul-
ation. 
Keywords: spectral analysis; molecular docking; protein–ligand interaction; 
protein stability, protein structure. 
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INTRODUCTION 
Human serum albumin (HSA) is the most dominant protein in the circul-
ation, with a concentration in the range from 35 to 50 g L–1 (522 to 746 µM). It 
has a molecular mass of 67 kDa.1 Structurally, HSA is composed of three homo-
logous domains (I, II and III), each divided into two subdomains, A and B. The 
dominant secondary structure motif of HSA is α-helix.2  
HSA has numerous essential functions in the circulation. Due to its high con-
centration, HSA participates in the regulation of osmotic pressure.3 Its free 
Cys34 thiol group (in healthy individuals 70–80 % of Cys34 thiol group is in a 
reduced form), makes HSA an important factor for plasma antioxidant capacity, 
contributing with 80 % to the total amount of plasma thiol.4 HSA is also a gen-
eral transporter of fatty acids, ions and many drugs. The structure of HSA 
enables it to accommodate and bind a large variety of small molecules with 
moderate to high affinities. Two main binding sites for many different molecules 
(excluding fatty acids) are located at the IIA subdomain or Sudlow I binding site, 
and IIIA subdomain or Sudlow II binding site. Warfarin and ibuprofen drugs are 
specific ligands for Sudlow site I and Sudlow site II, respectively.5  
Lipoic acid (LA) is a naturally occurring molecule the main sources of 
which are potato, broccoli and spinach. Humans can also synthesise LA in small 
amounts. LA is readily absorbed from foods and its oral administration as a drug 
is a viable therapeutic option, including the treatment of patients with Covid-19 
infection.6 LA supplements are also commercially available, with LA concentrat-
ions of up to 600 mg per tablet. The antioxidant activity of LA is manifested 
through ROS scavenging, transition metal ions (e.g., iron and copper) chelating, 
cytosolic glutathione and vitamin C level increases, and oxidative stress damage 
repair.7 
Following cellular uptake, LA is reduced to dihydrolipoic acid (DHLA), 
which is a very potent reducing agent.7 LA has several beneficial effects, such as 
antioxidant, improvement of glycaemic control, mitigation of toxicity by heavy 
metal poisoning and immunomodulatory effects.7–9  
Although the ability of albumin to bind DHLA is well known,10 no detailed 
analysis of this interaction has been reported so far. In the case of bovine serum 
albumin (BSA), DHLA was shown to bind at the IIIA subdomain.11 However, no 
binding experiments in the presence of a specific ligand for this site were per-
formed. Taking into account the structural similarity of DHLA and octanoic fatty 
acid, it was proposed that DHLA binds to subdomain IIA,12 but IIIA subdomain 
was also considered.11  
Considering that DHLA is a potent antioxidant used as a food supplement and 
that its usage can help in oxidative stress related conditions, it looked relevant to 
investigate its interaction with HSA, a universal transporter in the circulation. The 
properties of this interaction are still not fully defined in the literature. Hence, the 
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aim of the present study was to characterise DHLA–HSA binding, with the usage 
of both multi-spectroscopic and molecular modelling techniques. 
EXPERIMENTAL 
Materials 
All chemicals used were purchased from Sigma (Burlington, MA, USA) and were of ana-
lytical grade. HSA was purchased from Sigma, (product number A-1653), and used without 
additional purification. A stock solution was made in 10 mM phosphate buffered saline (PBS), 
pH 7.4. The concentration of HSA was determined using a bicinchoninic acid (BCA) assay kit 
(Thermo Fisher Scientific, Waltham, MA, USA). Stock solution (5 mM) of DHLA was prepared 
by suspending DHLA in 10 mM PBS following the addition of a small volume of 1 M NaOH 
until full clarification of solution was reached.13 Trypsin was purchased from the Torlak Institute 
(Belgrade, Serbia) as a 0.25 % solution. Stock solutions of ibuprofen and warfarin were made in 
DMSO. In the experiments where they were used, the final DMSO concentration did not exceed 
2 %. All experiments were performed in triplicate at room temperature, using 10 mM PBS, pH 
7.4, unless otherwise stated. All results are presented as averaged of triplicates, and their SD 
never exceeded 5 % of the presented averages. 
Analysis of HSA–DHLA complex formation by spectrofluorimetry 
Determination of the binding constant (Ka) of the HSA–DHLA complex was realised by 
measuring the quenching of the intrinsic fluorescence emission of HSA (0.4 µM) in the pre-
sence of increasing concentrations of DHLA (from 5 to 35 µM) at 37 °C. Fluorescence spectra 
were recorded using FluoroMax®-4 spectrofluorometer (Horiba Scientific, Japan). HSA was 
excited at 280 nm and the emission spectra were recorded in the range from 290 to 450 nm. 
Each spectrum was corrected for the emission of the control that contained only DHLA at a 
particular concentration. The change of the emission intensity at 338 nm (HSA emission 
maximum) was used for the calculation of the binding constant. The emission intensity mea-
sured for HSA was first corrected for the small inner filter effect of DHLA using the equation: 
 F = F010(Aex+Aem)/2 (1) 
where F is corrected fluorescence, F0 is measured fluorescence, Aex and Aem are absorbencies 
at excitation and emission wavelengths, which are 280 nm and 338 nm, respectively. 
The binding constant between HSA and DHLA was calculated using the following 
equation: 
 0 a L
c




  (2) 
where F0 and F represent the intensities of the fluorescence emission signals of HSA in the 
absence and the presence of the ligand, Fc represents the fluorescence intensity of HSA com-
pletely saturated with the ligand, which was experimentally obtained by determination of the 
fluorescence emission intensity of the protein in the presence of 17 mM DHLA and cL is the 
concentration of used ligand (DHLA). 
For determination, if at the same time, dynamic (collision) and static (complex formation) 
types of quenching are present or only one of them, Stern–Volmer (SV) graph was plotted. From 
it, the SV quenching constant (KSV) was calculated using the following equation:14 
 F0/F= 1 + kqτ0cQ = 1 + KSVcQ  (3) 
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where F0 and F are the intensities of the emission signals without and in the presence of 
DHLA, kq represents the biomolecule quenching rate constant, τ0 is the average lifetime of the 
biomolecule without quencher (10–8 s), cQ is the total concentration of quencher (DHLA). The 
slope from SV plot represents KSV. KSV was further used for the calculation of kq. 
Thermodynamic parameters of DHLA binding to HSA were calculated using the same 
experimental approach as for the calculation of Ka but at three different temperatures, 25, 30 
and 37 °C. The calculated binding constants at three temperatures were then used to plot a 
van't Hoff graph. Enthalpy (ΔH) and entropy (ΔS) change were calculated from the graph 




Δ Δ= − +   (4) 
where T is temperature in K and R is a universal gas constant (8.314 J mol-1 K-1). ΔH was 
calculated from the slope of van't Hoff graph and ΔS from the intercept.  
For fluorescence emission changes, specifically originating from Tyr residues or the only 
Trp214 residue, synchronous fluorescence spectra were recorded on RF-6000 spectrophoto-
meter (Shimadzu, Japan). The spectra were recorded in the range from 310 to 380 nm with Δλ 
of 60 nm for Trp and in the range from 290 to 325 nm with Δλ of 15 nm for the Tyr residues. 
Here, Δλ represents λ of emission – λ of the excitation for each specific residue.  
For the location of specific binding site(s), a competitive binding experiment was per-
formed. To HSA, increasing concentrations of DHLA in the presence and the absence of site 
ligands (ibuprofen and warfarin) were added. HSA (0.4 µM) was first incubated with 0.4 µM 
of site specific ligands and the obtained mixture were titrated with DHLA. HSA was excited 
at 280 nm and emission spectra were recorded in 290–450 nm range. Calculation of HSA– 
–DHLA affinity constants in the presence and absence of site-specific ligands was realized as 
already mentioned previously. 
In order to confirm that DHLA binds HSA at the binding site specific of warfarin, a mix-
ture of HSA (0.4 µM) and warfarin (20 µM) were titrated with DHLA (10, 20, 30, 40 µM). 
The warfarin fluorescence is enhanced in the presence of HSA and the excitation of the 
obtained complex was performed at 310 nm,15 while recording of emission spectra was per-
formed in the range 340–450 nm. The obtained spectra were corrected by subtracting the 
emission spectra obtained in the absence of HSA. 
UV–Vis analysis of the HSA–DHLA complex 
UV–Vis absorption spectra of HSA (9 µM), alone and in the presence of different con-
centrations of DHLA (9, 45 and 90 µM) were recorded at room temperature using a Ultrospec 
2000 spectrophotometer (Pharmacia Biotech, Sweden). The spectra were recorded in the 
wavelength range from 250 to 300 nm. The spectrum of each mixture was corrected for the 
spectrum obtained for the appropriate concentration of DHLA alone. Furthermore, the UV– 
–Vis spectrum of DHLA (90 µM) in the presence of HSA (9 µM) was recorded in the range 
from 300 to 450 nm and corrected for the spectrum obtained for HSA alone.  
Structural analysis of HSA–DHLA complex using circular dichroism (CD) spectropolarimetry 
The influence of DHLA binding on the structure of HSA was analysed using a CD-spec-
tropolarimeter J-815 (Jasco, Japan) at room temperature by applying a scan speed of 50 nm 
min-1. Different concentrations of DHLA were added (6, 15 and 30 µM) to HSA (3 µM). Both 
HSA and DHLA stock solutions were dissolved in 10 mM phosphate buffer, pH 7.4. The 
tertiary protein structure was analysed by recording near-UV CD spectra in the range from 
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260 to 320 nm using a cell with an optical path of 10 mm, while the secondary protein 
structure was monitored by recording far-UV CD spectra in the range 185–260 nm using a 
cell with 0.5 mm optical path length. The spectra of free ligand were subtracted from the 
spectra of corresponding protein–ligand mixtures.  
Analysis of temperature stability of HSA–DHLA complex 
Temperature stability of HSA (0.4 µM) alone and in the presence of DHLA (40 µM) was 
determined by recording the reduction of fluorescence emission at 338 nm (emission peak of 
HSA) and at 335 nm (emission peak of HSA–DHLA complex), using the same equipment as 
used in above. Reduction of protein emission was recorded in the temperature range from 37 
to 87 °C with a temperature increase rate of 2 °C min-1. At each temperature, the mixture was 
allowed to equilibrate for 1 min before the measurement. The obtained spectra were corrected 
by subtracting the spectra of DHLA recorded alone at each temperature. Results were fitted to 
sigmoid curves and from them inflexion points were obtained which represent melting 
temperatures of HSA (Tm). 
Analysis of proteolysis of HSA by trypsin in the presence of DHLA  
For the investigation of whether DHLA binding affects the susceptibility of HSA to tryp-
sin proteolysis, the following experiment was performed at 37 °C. To solutions containing 4 
µM HSA, alone and in the presence of DHLA (40 µM), 25 µL of 0.25 % trypsin solution was 
added. The final volume of reaction mixtures was 1 mL. At different time points (1, 5, 10, 20 
and 30 min), 50 µL aliquots were taken from the reaction mixture and PMSF immediately 
added at the final concentration of 2 mM, thus stopping the reaction. Proteolytic fragments of 
HSA were analysed by reducing SDS-PAGE using a 12 % gel in a standard manner. The gel 
was stained using the Silver Stain Plus Kit (Bio-Rad, Hercules, California, USA). 
Molecular docking and dynamic analysis  
The methods used and the obtained results are given in the Supplement material to this 
paper. 
RESULTS AND DISCUSSION 
HSA–DHLA complex formation 
The intrinsic fluorescence of HSA is quenched in the presence of DHLA, as 
shown in Fig. 1A. In addition, a small blue shift (3 nm) of the emission maxi-
mum of HSA is observed, in the presence of increasing concentrations of DHLA. 
The obtained results indicate that HSA is capable of binding DHLA and by doing 
so, the polarity in the vicinity of Tyr and Trp214 amino acid residues of HSA is 
not significantly changed. Fluorescence quenching can occur as a result of dyn-
amic quenching (collisional) and static quenching (complex formation), whereby, 
both of them can be present simultaneously. To determine what applies for the 
present HSA–DHLA pair, an SV graph was plotted (Fig. 1B) and from its slope, 
KSV was determined. Since the obtained SV plot is linear (r2 = 0.99), it proves 
that only one quenching type occurs in our tested system. KSV was determined to 
be 0.83×104 M–1 and from it, the quenching rate constant of the biomolecule, kq, 
was determined to be 0.83×1012 M–1. The obtained value of kq is about two 
orders of magnitude higher than the diffusion rate of biomolecules (1010 M–1 s–1), 
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strongly suggesting the presence of a static type of quenching or, in other words, 
complex formation between HSA and DHLA.16 By using Eq. (2) and the plot 
from Fig. 1C, Ka was determined to be 1.00±0.05×104 M–1, at 37 °C, showing 
that HSA can bind DHLA with a moderately strong affinity. 
 
Fig. 1. Binding analysis of HSA and DHLA using spectrofluorimetry. Fluorescence emission 
spectra of HSA (excited at 280 nm) in the presence of increasing concentrations of DHLA 
(A). Stern–Volmer plot (B) and the plot used to determine the binding constant between HSA 
and DHLA (C) obtained using the fluorescence emission maximum of HSA at 338 nm. van't 
Hoff's graph, obtained by calculating the binding constants between HSA and DHLA at three 
different temperatures (D). 
Calculation of Ka at three different temperatures showed that its value dec-
reased as a consequence of temperature increase. This usually occurs when the 
static type of quenching is present since formation a complex is weaker at higher 
temperatures.17 This result also confirms complex formation between HSA and 
DHLA. From the Ka values obtained at three temperatures, thermodynamic para-
meters were determined using a van't Hoff plot (Fig. 1D). A negative value of 
ΔH was obtained, –4.42 kJ mol–1 and positive value of ΔS, 62.27 J mol–1 K–1. 
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These results indicate that electrostatic interactions are key interactions for HSA– 
–DHLA complex formation,18 which was also confirmed by molecular dynamic 
analysis. 
Synchronous fluorescence spectra are used to provide information about the 
changes in the emission of Trp and Tyr amino acid residues. HSA has only one 
Trp residue that is located inside the binding site of subdomain IIA (Sudlow I 
binding site),19 and information from synchronous spectra can provide insight 
into the binding site for a certain ligand. Increasing concentrations of DHLA sig-
nificantly quenched emission spectrum of Trp (Fig. 2A), while quenching of 
emission spectrum of Tyr occurred to a very small extent (Fig. 2B). Bearing in 
mind the location of the only Trp residue in HSA, this result suggested that 
DHLA binds HSA at the subdomain IIA binding site (Sudlow I binding site). 
 
Fig. 2. Determination of a binding site of DHLA on HSA. Synchronous fluorescence spectra 
of HSA with Δλ = 60 nm for Trp (A) and Δλ = 15 nm for Tyr (B) in the presence of increasing 
concentrations of DHLA. Relative affinity constants for HSA–DHLA complex formation 
calculated for 0.4 µM HSA alone and in the presence of equimolar concentrations of warfarin 
and ibuprofen, respectively (C). Displacement of HSA-bound warfarin by increasing 
concentrations of DHLA, detected by specific excitation of warfarin at 310 nm and recording 
its emission in the range from 340 to 450 nm (D). 
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For determination the binding site, DHLA was added to HSA in the presence 
of warfarin and ibuprofen. The affinity constant of HSA–DHLA complex in the 
presence of these molecules was calculated as described previously. Binding of 
both warfarin and ibuprofen to HSA is well characterised with affinity constants 
of about 105 M–1 for warfarin,20 and about 106 M–1 for ibuprofen.21 As warfarin 
binds specifically to subdomain IIA binding site (Sudlow I) on HSA, while ibu-
profen specifically binds to subdomain IIIA binding site (Sudlow II), they are 
used to block these sites in the studies that aim to locate the exact binding sites 
for other ligands.5 The obtained results, Fig. 2C, show that in the presence of 
warfarin, the affinity constant for the HSA–DHLA complex is reduced by almost 
25 %, while ibuprofen only marginally reduced this value, about 5 %. Therefore, 
although the binding constant of warfarin to HSA is one order of magnitude 
lower than ibuprofen, the presence of warfarin has a five times more pronounced 
effect on the decrease of DHLA binding affinity to HSA in comparison to the 
presence of ibuprofen. Hence, these results show that DHLA preferentially binds 
at subdomain IIA on HSA.  
The fluorescence intensity of warfarin increases when bound to HSA, Fig. 
2D. This usually happens when a ligand binds to a protein and by doing so it 
becomes located in a more hydrophobic environment and thus shielded from 
water.22 A similar observation was noted for the binding of phycocyanobilin 
(PCB) to HSA, which happens at binding sites of both IIA and IB subdomains of 
HSA.23 In the presence of increasing concentrations of DHLA, a reduction in the 
emission intensity of warfarin occurs, (Fig. 2D) indicating that DHLA displaces 
warfarin from its binding site, confirming that HSA binds DHLA at subdomain 
IIA.  
The presence of aromatic amino acid residues enables proteins to absorb 
light in the UV region at about 280 nm and alterations in the absorption spectrum 
in this region may occur due to changes in the polarity of the environment that is 
in vicinity to these residues. The UV–Vis absorption spectrum of HSA does not 
change in the presence of increasing concentrations of DHLA, Fig. 3A, indi-
cating that the binding of DHLA to HSA did not have any significant effect on 
the polarity or aromatic amino acids of HSA, which is in agreement with results 
obtained by spectrofluorimetry (Fig. 3A). The absorption spectrum of DHLA 
changes in the presence of HSA. Its peak is blue shifted and its intensity is 
reduced (Fig. 3B). Similarly, this was observed previously upon DHLA binding 
to fibrinogen.24 Changes in the absorption spectrum of DHLA represent addit-
ional proof that the HSA–DHLA complex is being formed.  
Influence of DHLA binding on the stability and structure of HSA 
Often, ligand binding has effect on the protein structure, with some ligands 
inducing more ordered structures, others causing the protein to be more disordered,  
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Fig. 3. The influence of complex formation on the UV-VIS absorption spectra of HSA and 
DHLA. UV absorption spectra of HSA alone and in the presence of increasing concentrations 
of DHLA (A). UV–Vis absorption spectra of DHLA alone and in the presence of HSA (B). 
while some ligands have no effect. HSA has only α-helixes as the secondary 
structure motifs. Binding of amoxicillin and PCB to HSA increases its α-helical 
content,25 while binding of safranal and crocin decreases it.19 Far-UV CD 
spectra, obtained for HSA, (Fig. 4A), show a typical protein signal with α-helix 
as the dominant secondary structure motif. Its characteristic is a wide negative 
peak, ranging from 209 to 220 nm. From Fig. 4A, it can be seen that DHLA 
binding to HSA has no significant change in the secondary structure of HSA, 
even in the presence of ten times larger molar concentration of DHLA than HSA. 
The obtained near-UV-CD spectra for HSA alone and in the presence of all 
tested concentrations of DHLA are practically the same, showing that the tertiary 
structure of HSA upon DHLA binding is unaltered (Fig. 4B). 
Besides the protein structure, other factors that affect the melting point of a 
protein may include the presence of bound molecules as well as their own struc-
ture. As a consequence of protein–ligand complex formation, new interactions are 
formed, and they may alter the temperature stability of the protein. Free HSA has a 
Tm of about 62 °C, while with bound fatty acids, its temperature stability increases, 
reaching a Tm from 64 to 72 °C.26 Some ligands, such as embelin and PCB, are 
also able to increase the temperature stability of HSA.25,27 The HSA used in this 
study had a Tm of 68 °C. When bound to DHLA, the Tm of the HSA is increased to 
70 °C (Fig. 4C). Since DHLA did not have any effect on the structure of HSA upon 
its binding (Figs. 4A and 4B), it seems that newly formed interactions in the HSA– 
–DHLA complex caused additional thermal stabilisation of HSA.  
Since the Tm of HSA increased in the presence of DHLA, indicating that the 
protein is becoming more rigid, this in turn may affect its susceptibility to proteo-
lysis. For a protein to be proteolysed, its peptide bonds need to be exposed enough 
to enable their proper placement in the active site of a protease. Some ligands, such 
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as bilirubin for example, can make HSA more resistant to cleavage by trypsin.28 
From the obtained results, it seems that DHLA, although it thermally stabilises 
HSA, has no significant effect on HSA proteolysis by trypsin (Fig. 4D). This 
suggests that the binding of DHLA to HSA will not have significant (if any) effect 
on the half-life of this protein in circulation, regarding proteolysis. The first and the 
most dominant fragment of HSA resulting from its proteolysis by trypsin is the one 
at about 5 kDa. Other, less abundant fragments, with lower molecular masses 
appear later. This finding is in agreement with literature data.25  
 
Fig. 4. Analysis of structural alterations of HSA due to DHLA binding. Far-UV CD (A) and 
near-UV CD (B) spectra of HSA alone and in the presence of increasing concentrations of 
DHLA. Temperature stability of HSA alone and in the presence of DHLA (C). Analysis of 
HSA digestion by trypsin in the absence (lanes 1–5, samples were taken after 1, 5, 10, 20 and 
30 min of proteolysis) and in the presence of DHLA (lanes 6–10) by reducing SDS-PAGE on 
12 % gel (D). MM stands for molecular weight markers. 
HSA can be oxidised, and the small structural changes that arise as a con-
sequence of this chemical modification can lead to an impairment of HSA func-
tions, including its important ligand-binding ability.29 The binding properties of 
HSA can also be influenced by the redox state of its free Cys34.30 Considering 
the high concentration of HSA and its capacity to bind a large range of small 
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molecules, changes in its binding properties may have significant consequences 
on pharmacokinetic and pharmacodynamic (PKPD) properties of prescribed 
drugs. The ability of DHLA to protect albumin from non-enzymatic glycosyl-
ation10 and methylglyoxal modification31 was previously shown. Additionally, 
DHLA could protect Cys34 from oxidation.12 Thus, by complex formation with 
HSA, DHLA can prevent the oxidation of HSA, and also preserve the antioxid-
ative and binding properties of HSA. Considering its popular usage as a food 
supplement, detailed knowledge of the PKPD properties of DHLA is very imp-
ortant, including information on its binding proteins in the circulation.  
CONCLUSIONS 
The results of this paper characterise, in more detail, complex formation 
between DHLA and HSA, which was lacking in the literature. The obtained 
results showed that preferential binding on HSA of DHLA is located at sub-
domain IIA (Sudlow I binding site). The ability of the Sudlow I site to bind 
DHLA and the stability of the formed complex was confirmed by molecular 
docking analysis and dynamics. The structure of HSA is not significantly altered 
on DHLA binding, however, HSA is stabilised. The presence of DHLA did not 
alter the susceptibility of HSA towards trypsin proteolysis and hence, no change 
of half-life of HSA in circulation due to proteolysis, is expected. These results 
add to the knowledge of the PKPD properties of DHLA and offer a future per-
spective for further studies that deal with the usage of DHLA as a food sup-
plement. 
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У раду су описане карктеристике везивања дихидро-липоинске киселине (DHLA), 
познатог суплемента у исхрани и антиоксиданса, за албумин из серума људи (HSA). 
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Процес везивања је праћен применом већег броја спектроскопских метода и молекул-
ским моделовањем. HSA везује DHLA умереним афинитетом, 1,00±0,05×104 M-1. Спек-
троскопски резултати су показали да је везујуће место IIA (Sudlow I) главно место вези-
вања DHLA за HSA. Експериментални, као и резултати молекулског моделовања, су 
идентификовали електростатичке (сони мостови) и водоничне везе као главне типове 
интеракција. Резултати молекулског моделовања су потврдили да и место Sudlow I може 
везати DHLA, која је у том случају у специфичној конформацији. Симулација моле-
кулске динамике је показала да је формирани комплекс стабилан. Везивање DHLA не 
утиче на структуру протеина, али повећава његову термалну стабилност. Везани DHLA 
не утиче на подложност HSA трипсинској дигестији. Како је DHLA уобичајен суплемент 
у исхрани, знање о његовим фармакоконетичким и фармакодинамичким особинама је 
веома важно. Ово испитивање допуњује досадашња знања детаљном анализом интер-
акције DHLA са HSA, примарним транспортним протеином лекова у циркулацији. 
(Примљено 22. априла, ревидирано и прихваћено 27. маја 2021) 
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